Sensitivity of undetectable level of high-sensitivity troponin T at presentation in a large non-ST-segment elevation myocardial infarction cohort of early presenters.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 06 2019
Historique:
received: 01 06 2018
revised: 26 09 2018
accepted: 25 10 2018
pubmed: 11 11 2018
medline: 7 1 2020
entrez: 11 11 2018
Statut: ppublish

Résumé

We aimed to evaluate the diagnostic sensitivity for myocardial infarction (MI) when using an undetectable level of high-sensitivity cardiac troponin T (hs-cTnT < 5 ng/L) at presentation combined with a non-ischemic electrocardiogram (ECG), to rule out MI in a non-ST-segment elevation MI (NSTEMI) cohort presenting ≤2 h from symptom onset. We also aimed to compare baseline characteristics and 30-day outcome in NSTEMI patients presenting with and without hs-cTnT < 5 ng/L. All patients admitted to five centers in Sweden 2011-2015, after the introduction of hs-cTnT, who presented ≤2 h from symptom onset and received a final diagnosis of NSTEMI, were identified through the SWEDEHEART registry. These data and data of hs-cTnT levels were verified in the hospitals' medical records. The registry provided baseline and outcome data. Twenty-four (2.6%) of 911 NSTEMI patients presented with hs-cTnT < 5 ng/L. In patients presenting >1-≤2 h from symptom onset the sensitivity for MI when combining hs-cTnT and ECG was 99.4% (95% CI 98.4%-99.8%). In patients presenting ≤1 h, and in patients aged ≤65 years without prior MI, the sensitivity was insufficient. NSTEMI patients presenting with hs-cTnT < 5 ng/L were younger and had less often a prior MI. A total of 62.5 vs. 63.5% of the NSTEMI patients presenting with and without hs-cTnT < 5 ng/L underwent revascularization within 30 days and 4.5 and 3.2% died respectively. Hs-cTnT < 5 ng/L at presentation combined with a non-ischemic ECG may be used to rule out MI in patients presenting as early as >1 h from symptom onset with a sufficient sensitivity.

Sections du résumé

BACKGROUND
We aimed to evaluate the diagnostic sensitivity for myocardial infarction (MI) when using an undetectable level of high-sensitivity cardiac troponin T (hs-cTnT < 5 ng/L) at presentation combined with a non-ischemic electrocardiogram (ECG), to rule out MI in a non-ST-segment elevation MI (NSTEMI) cohort presenting ≤2 h from symptom onset. We also aimed to compare baseline characteristics and 30-day outcome in NSTEMI patients presenting with and without hs-cTnT < 5 ng/L.
METHODS
All patients admitted to five centers in Sweden 2011-2015, after the introduction of hs-cTnT, who presented ≤2 h from symptom onset and received a final diagnosis of NSTEMI, were identified through the SWEDEHEART registry. These data and data of hs-cTnT levels were verified in the hospitals' medical records. The registry provided baseline and outcome data.
RESULTS
Twenty-four (2.6%) of 911 NSTEMI patients presented with hs-cTnT < 5 ng/L. In patients presenting >1-≤2 h from symptom onset the sensitivity for MI when combining hs-cTnT and ECG was 99.4% (95% CI 98.4%-99.8%). In patients presenting ≤1 h, and in patients aged ≤65 years without prior MI, the sensitivity was insufficient. NSTEMI patients presenting with hs-cTnT < 5 ng/L were younger and had less often a prior MI. A total of 62.5 vs. 63.5% of the NSTEMI patients presenting with and without hs-cTnT < 5 ng/L underwent revascularization within 30 days and 4.5 and 3.2% died respectively.
CONCLUSIONS
Hs-cTnT < 5 ng/L at presentation combined with a non-ischemic ECG may be used to rule out MI in patients presenting as early as >1 h from symptom onset with a sufficient sensitivity.

Identifiants

pubmed: 30413299
pii: S0167-5273(18)33552-6
doi: 10.1016/j.ijcard.2018.10.088
pii:
doi:

Substances chimiques

Biomarkers 0
Troponin T 0

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

6-11

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Lina Ljung (L)

Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, SE-118 83 Stockholm, Sweden; Department of Cardiology, Södersjukhuset, SE-118 83 Stockholm, Sweden. Electronic address: lina.ljung@sll.se.

Camilla Reichard (C)

Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, SE-182 88 Danderyd, Sweden.

Peter Hagerman (P)

Department of Emergency Medicine, Capio S:t Göran's Hospital, SE-112 81 Stockholm, Sweden.

Kai M Eggers (KM)

Department of Medical Sciences, Uppsala University, SE-751 85 Uppsala, Sweden.

Mats Frick (M)

Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, SE-118 83 Stockholm, Sweden; Department of Cardiology, Södersjukhuset, SE-118 83 Stockholm, Sweden.

Bertil Lindahl (B)

Department of Medical Sciences, Uppsala University, SE-751 85 Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, SE-752 37 Uppsala, Sweden.

Rikard Linder (R)

Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, SE-182 88 Danderyd, Sweden.

Arne Martinsson (A)

Department of Emergency Medicine, Capio S:t Göran's Hospital, SE-112 81 Stockholm, Sweden.

Dina Melki (D)

Heart and Vascular Theme, Karolinska University Hospital, SE-141 86 Stockholm, Sweden.

Per Svensson (P)

Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, SE-118 83 Stockholm, Sweden; Department of Cardiology, Södersjukhuset, SE-118 83 Stockholm, Sweden.

Tomas Jernberg (T)

Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, SE-182 88 Danderyd, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH